

PHARMACEUTICAL 2023

Nuvation Bio Inc. Rank 9 of 446









PHARMACEUTICAL 2023

Nuvation Bio Inc. Rank 9 of 446



The relative strengths and weaknesses of Nuvation Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nuvation Bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 63% points. The greatest weakness of Nuvation Bio Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 296%, being 253% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	667,318
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,161
Liabilities, Non-Current	3,054
Other Assets	3,929
Other Compr. Net Income	-4,341
Other Expenses	0
Other Liabilities	850
Other Net Income	15,535
Other Revenues	0
Property and Equipment	894
Research and Development	87,815
Selling, General and Administrative Expense	31,919

Output Variable	Value in 1000 USD
Assets	672,141
Liabilities	17,065
Expenses	119,734
Revenues	0
Stockholders Equity	655,076
Net Income	-104,199
Comprehensive Net Income	-106,370
Economic Capital Ratio	296%

